The priming of an immune response against a major histocompatibility complex class I-restricted antigen expressed by nonhematopoietic cells involves the transfer of that antigen to a host bone marrow-derived antigen presenting cell (APC) for presentation to CD8 + T lymphocytes. Dendritic cells (DC), as bone marrow-derived APC, are first candidates for presentation of tumorassociated antigens (TAA). The aim of this study was to see whether DC are able to prime in vivo antigen-specific cytotoxic T lymphocytes after exposure to a soluble protein antigen in vitro. Lacking a well-defined murine TAA, we took advantage of 13-galactosidase (13-gal)-transduced tumor cell lines as a model in which [3-gal operationally functions as TAA. For in vivo priming both a DC line, transduced or not transduced with the gene coding for murine GM-CSF, and fresh bone marrow-derived DC (bm-DC), loaded in vitro with soluble ~-gal, were used. Priming with either granulocyte macrophage colony-stimulating factor-transduced DC line or fresh bm-DC but not with untransduced DC line generated CTL able to lyse 13-gal-transfected target cells. Furthermore, GM-CSF was necessary for the DC line to efficiently present soluble [3-gal as an H-2Ld-restricted peptide to a [3-gal--specific CTL clone. Data also show that a long-lasting immunity against tumor challenge can be induced using [3-gal-pulsed bm-DC as vaccine. These results indicate that effector cells can be recruited and activated in vivo by antigen-pulsed DC, providing an efficient immune reaction against tumors.
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SumlTlary
The priming of an immune response against a major histocompatibility complex class I-restricted antigen expressed by nonhematopoietic cells involves the transfer of that antigen to a host bone marrow-derived antigen presenting cell (APC) for presentation to CD8 + T lymphocytes. Dendritic cells (DC), as bone marrow-derived APC, are first candidates for presentation of tumorassociated antigens (TAA). The aim of this study was to see whether DC are able to prime in vivo antigen-specific cytotoxic T lymphocytes after exposure to a soluble protein antigen in vitro. Lacking a well-defined murine TAA, we took advantage of 13-galactosidase (13-gal)-transduced tumor cell lines as a model in which [3-gal operationally functions as TAA. For in vivo priming both a DC line, transduced or not transduced with the gene coding for murine GM-CSF, and fresh bone marrow-derived DC (bm-DC), loaded in vitro with soluble ~-gal, were used. Priming with either granulocyte macrophage colony-stimulating factor-transduced DC line or fresh bm-DC but not with untransduced DC line generated CTL able to lyse 13-gal-transfected target cells. Furthermore, GM-CSF was necessary for the DC line to efficiently present soluble [3-gal as an H-2Ld-restricted peptide to a [3-gal--specific CTL clone. Data also show that a long-lasting immunity against tumor challenge can be induced using [3-gal-pulsed bm-DC as vaccine. These results indicate that effector cells can be recruited and activated in vivo by antigen-pulsed DC, providing an efficient immune reaction against tumors.
T he cloning of genes encoding tumor-associated antigens (TAA) recognized by T cells in both humans and rodents (1, 2) have reopened the never-ending hope of curing cancer through immunological interventions. Active immunization with such antigens is expected to activate tumor-specific CTL, a process requiring T cell priming in the context of MHC class I pathway (3). CTL induction usually follows antigen processing via endogenous pathway, although exceptions have been reported (4, 5) . Host bone marrow-derived APC induced in vivo a CTL-mediated protective immunity against an MHC class I-negative tumor by uptaking and processing for presentation within their own MHC-I (6). Among bone marrowderived APC, dendritic cells (DC) are the most attractive candidates for this purpose since several studies suggest that they are particularly effective in stimulating both CD4 + A preliminary account of this work was presented to the Keystone Symposia Conference on Dendritic Cells: Antigen-presenting Cells of T and B Lymphocytes, in Taos, NM, 10-16 March 1995. and CD8 § naive T lymphocytes (7) (8) (9) (10) (11) (12) . In fact DC express the costimulatory molecules B7.1 and B7.2, adhesion molecules, and may release soluble factors, all needed for an efficient triggering of the immune response (13) . Furthermore, DC were shown to be necessary to generate T cellmediated tumor-specific immunity in some murine models (14) (15) (16) . This response was dominated by CD4 + T cells and was generally unable to completely inhibit tumor take unless, as in the case of BCL1 lymphoma, an antiidiotypic antibody response can be generated (16) . This limited effect on tumors could be due to the incomplete activation of CD8 § T cells, and particularly of CTL, which are considered as the main effectors able to destroy tumor cells in vivo (3) . DC, exposed to soluble antigen in vitro, are able to sensitize antigen-specific T lymphocytes in vivo, in an MHC-II-restricted fashion (7) . Since CTLs appear to be necessary to induce tumor rejection in several animal models, we addressed the question of whether DC pulsed in vitro with a soluble antigen were able to induce cytolytic MHC-I-restricted CD8 + T cells as well as a protective antitumor immunity in vivo.
Materials and Methods
Animals. Female BALB/c (H-2 a) of 8 and 12 wk of age were purchased from Charles River Laboratories (Calco, Italy). This study was approved by the Institutional Ethic Committee for the use of animals in experimental research.
Cell Lines. D2SC/1 (H-2 d) is a DC line obtained by retroviral immortalization of BALB/c spleen-derived DC, through a previously described procedure (17) , and generously provided by Dr. P. Ricciardi-Castagnoli (Consiglio Nazionale delle Ricerche, Milano, Italy). D2SC/I-GM was obtained by transduction of D2SC/1 cell line with the retroviral vector LmGMSN. GM-CSF cDNA was obtained from a murine CTL line by reverse transcription PCR using GM-CSF-specific primer ends modified to include EcoRI and BamHI sites at 5' and 3', respectively. The resulting 517-bp GM-CSF insert was ligated into EcoRI and BamHI of the LXSN retroviral vector (18) , to obtain the LmGMSN vector. Retroviral particles were obtained by transinfection technique, as described (19, 20 (22) were kindly provided by Professor H. G. 1Kammensee (Deutsches Krebsforschungzentrmn, Heidelberg, Gemaany). P815 (H-2 a) and EL4 (H-2 b) tumor lines were used as negative control targets in SICr release assay. All cells were maintained in RPMI 1640 supplemented with 10% FCS except for DC lines, which were grown in 5% 1=CS-supplemented IMDM. The synthetic peptide ~GP1 ([3-gal, p876-884, TPHPARIGL) was a generous gift of Dr. N. 1Kestifo (National Cancer Institute, Bethesda, MD).
Bone Marrow DC Preparation. Fresh DC were obtained from mouse bone marrow precursors as previously described (23) . Bone marrow-derived (bm) DC were used for in vivo priming after 9-11 d of in vitro maturation driven by recombinant mouse GM-CSF at 500 U/ml. The percentage of mature DC was determined by cell surface and intracellular antigens staining and ML1K assay as previously described (17) . Preparations always resulted in >90% potent MLR stimulator DC (not shown).
Immunization and CTLAssay. Before injection in vivo, DC lines as well as fresh bm-DC were exposed in vitro to 100 b~g/ml 13-gal grade X (Sigma Chemical Co., Milano, Italy) for 18-20 h to allow protein processing. Flow Cytometry. The CD4/CD8 profile of in vivo primed T lymphocytes were analyzed by flow cytometry after conventional mAb staining (17) . The following mAbs were used: FITC-conjugated anti-CD4, clone 1KM4-5, and anti-Thyl.2, clone 53-2.1, and PE-conjugated anti-CD8, clone 53-6.7 (Pharmingen, San Diego, CA). Analysis was performed on a FACScan | (BectonDickinson, Milano, Italy); data were collected on 5,000-10,000 viable cells and analyzed using Lysis 1I | software. To detect cell surface expression of leukocyte markers on DC cell lines, immunostaining was performed as previously described (17) using the following mAbs: M1/42, anti-MHC-I; B21.2, anti-MHC-II (IAb'd); 2D2C, anti-CD44; M1/69, anti-heat-stable antigen; 3E2, anti-ICAM-1; 1G10, anti-B7-1; GLI, anti-B7-2; and unrelated isoWpe-matched mAbs as controls.
In Vivo Protection Studies. Mice were immunized following the schedule of Table 1 , and control naive animals received in the left rear flank a subcutaneous challenge of F1.All living cells (104) 10-12 d after vaccination. Mice given the tumor subcutaneously were inspected for tumor growth and size twice a week. The differences in tumor take between control and imnmnized mice were statistically evaluated by chi-square test, considering a X 2 value >3.8 as indicative of significant difference at <0.05 level. 
Results
The DC Line D2SC/1 Exposed to Soluble fl-gal In Vitro Primes an Antigen-specific Cytolytic T Cell Response after a Single Immunization In Vivo.
To assess the ability of DC to prime a CTL response against a soluble protein in vivo, mice were injected intraperitoneally with 2-5 • 106 D2SC/ 1 or D2SC/1-GM cells previously exposed in vitro to soluble ]3-gal. 10-12 d after immunization, mice were killed and their spleen cells harvested and placed in secondary culture in vitro. As expected, a CD4-mediated [3-gal-specific proliferative response was elicited (Fig. 1 A) . To assess cytolytic activity, splenocytes from vaccinated mice were placed in a secondary in vitro culture with the [3-gal synthetic peptide [3GP1, or ~-gal gene-transduced tumor cells (not shown), and tested, 5 d later, for lytic activity on 13-gal-transfected P13.1 and parental P815 cells (Fig. 1 B) . Splenocytes from mice primed in vivo with D2SC/1 cells + [3-gal were unable to specifically lyse P13.1 whereas splenocytes from mice primed with D2SC/1-GM + [3-gal lysed P13.1 but not P815. Thus only the priming with the GM-CSF-transduced cell line elicited antigen-specific CTL. Vaccination with DC lines not pulsed with the soluble protein did not induce [3-gal-specific CTL, while a proliferative response against FCS components could not be avoided.
GM-CSF Allows the In Vitro MHC-I-restricted Presentation of Soluble Antigen by D2SC/1 Cell Line.
Further investigation of the effect of GM-CSF transduction on the DC line D2SC/1 did not reveal modifications in the pattern of cell surface markers but, as "already observed after addition of recombinant mouse GM-CSF to another immortalized cell line (17), GM-CSF-transduced DC became free in suspension and acquired a more dendritic morphology (not shown).
Moreover, that GM-CSF modifies the ability of D2SC/1 to present [3-gal was clearly shown by experiments in which D2SC/1 and D2SC/1-GM pulsed with either [3GP1 peptide or soluble [3-gal were used as targets of the [3-gal-specific, CTL clone 0805.B. In fact, while both D2SC/1 and D2SC/1-GM were lysed if pulsed with the peptide [3GP1 (Fig. 2 A) , only D2SC/1-GM was lysed after pulsing with soluble [3-gal (Fig. 2 B) . This result clearly indicates that the peptide was correctly displayed within the 
Fresh bm-DC Process Soluble fl-gal In Vitro and Prime Antigen-specific CTL In Vivo.
To investigate whether the in vivo priming of CTL is a property restricted to immortalized DC lines, experiments were run in parallel by using bm-DC. Fresh DC were exposed to soluble antigen in vitro with the same procedure and concentration used for D2SC/1 cells and injected intraperitoneally in BALB/c mice (Table 1) . 500,000 bm-DC, pulsed in vitro with soluble ~-gal, were sufficient to prime antigen specific CTL in vivo, whereas no evidence of CTL activation was seen in mice immunized once or twice with soluble [3-gal or with unloaded bm-DC (Fig. 3) .
Lymphocytes primed in vivo with DC and expanded by secondary in vitro cultures, were enriched in T cells. Particularly, we found that CD8 + cells were 55-70% and 15-35% in DC versus tumor cell-primed lymphocytes, respectively. Furthermore, lymphocytes from mice primed with DC showed a blastlike morphology, indicating a probable entry in G1 phase, since their forward scatter/side scatter parameters were 500:250 while parameters of lymphocytes from mice primed with tumor cells were 200 : 50, the latter without a significant difference from naive lymphocyte size (Table 2) . (Fig. 4 A) . Vaccination with soluble [3-gal admixed with CFA or Corynebacterium parvum adjuvants did not result in tumor protection (Fig. 4 B) .
Vaccination with DC Pulsed with fl-gal Protects
Discussion
To directly investigate the in vivo priming of a CD8-mediated T cell response after prophylactic vaccination with soluble protein loaded DC, we took advantage of a previously described immortalized DC line (17) to set up the model, and from the complete set of reagents that an antigen like [3-gal may offer. In fact, [3-gal-soluble protein, its immunogenic peptide as well as a retroviral vector able to transduce the gene into tumor cells, were all available. In addition, [3-gal has been chosen because, as soluble protein, it lacks intrinsic properties that allow its entry into the cell outside the endosomal compartment and because it is unable to stimulate CTL in vivo (5). We observed that DC lines loaded in vitro with soluble antigen were able to activate antigen-specific CTL if transduced with GM-CSF gene. This confirms previous observations which indicate GM-CSF as a "pro-presentation" cytokine (25) . In fact, GM-CSF is able to enhance the immune response initiated by DC, including immunity against tumors, by directly stimulating maturation of their accessory properties (15, 26) . Availability of DC lines either transduced or not with the GM-CSF gene was instrumental to define clearly the role of GM-CSF, since bm-DC could be obtained only in the presence of GM-CSF, thus lacking the control counterpart. Our results demonstrate that GM-CSF can activate a pathway of antigen processing that allows exogenous soluble protein to be presented by MHC-I molecules as shown by the recognition and killing of GM-CSF-transduced DC loaded with soluble [3-gal by a CTL clone specific for the [3-gal, H-2Ld-restricted epitope. Furthermore, CTL activation in vivo was obtained by vaccination with fresh bm-DC loaded with soluble [3-gal in vitro, and vaccinated mice were completely protected against live tumor challenge if boosted with the soluble antigen. Here, GM-CSF was necessary to drive maturation of DC in vitro, while antigen boost shows that concomitant recall ofDC-primed T helper cells is likely to Figure 4 . Ability of immunized mice to reject a 13-galexpressing tumor challenge. After immunization with the indicated vaccine, BALB/c mice were injected subcutaneously with 104 F1.A11 tumor cells. Tumor growth was inspected twice a week by palpation. Seven mice were included in each group. *Statistically not different; **P <0.05; ***P <0.01.
be beneficial for sustaining a protective immune response against tumors as it was shown to occur for the induction of reaction against influenza virus in vitro (27) . Along with CTL, Th were certainly activated by immunization with [3-gal-loaded DC since both antigen-specific CD4 + T cell proliferation and anti-13-gal antibody production were observed (not shown).
That [3-gal could be considered a model to overcome the limited availability of well-characterized tumor antigen in the mouse is supported by our preliminary results showing that bm-DC pulsed with a 20-met length peptide encompassing the Arg 12 mutation of the K-ras oncogene which, by itself, can not be accommodated within the MHC-I groove, immunize naive mice against a fibrosarcoma carrying this mutation (Carbone, G., et al., manuscript in preparation). Identification and cloning of tumor antigens expressed by melanomas (2) and identification of immunogenic peptides within mutated or overexpressed oncogenes, i.e., RAS and HER-2/neu (3), prompted the possibility to immunize cancer patients with well-defined T cell epitopes. Since immunogenicity of antigenic peptides may depend on the type of adjuvant, pulsed DC may represent the ideal cell-based vaccine even for human tumors, especially now that obtaining a consistent number of DC from human CD34 + precursor by CSF administration is possible (28) .
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